Efficacy and Safety of 1-year Duration of DAPT After GENOSS® DES Implantation in Patients with Coronary Artery Disease According to the Complex Higher-risk Procedure

Recruiting now

Conditions studied: Coronary Artery Disease, Percutaneous Coronary Intervention, Dual Antiplatelet Therapy

In brief

The objective of study is to evaluate the efficacy and safety of 1 year duration of DAPT after GENOSS® DES Implantation in patients with coronary artery disease according to the complex higher-risk (and indicated) procedure.

Key facts

Study ID

NCT06075433

Run by

Genoss Co., Ltd.

People needed

1000

Starts

2022-05-13

Expected to finish

2027-12-31

Last updated by the study team

2025-02-21

Who can join

Age: 19 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Patients of 19 and over
• Patients with coronary artery disease treated with GENOSS SES
• Participants who voluntarily decide to participate in this clinical trial, agree to the study protocol and clinical follow-up plan, and provide written informed consent as study participants

You may not qualify if…

• Patients with cardiogenic shock at the time of hospitalization
• Patients who are pregnant or planning to become pregnant
• Patients with a life expectancy of less than 1 year
• Patients participating in randomized controlled trials using other medical devices
• Patients who have already received treatment with another DES (Drug Eluting Stent) or BMS (Bare Metal Stent) at the time of registration (However, other stent insertions are allowed due to failure of GENOSS DES insertion)

Where it is running

• Wonju Severance Christian Hospital — Wŏnju, Gangwon State, South Korea (enrolling)

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.